twelve vs 48 months of dual antiplatelet therapy after drug-eluting stent placement the optidual...
TRANSCRIPT
Twelve vs 48 months of dual antiplatelet therapy after drug-eluting stent placement
The OPTIDUAL randomized trial
Gérard HELFTon behalf of the OPTIDUAL Investigators
Institut de Cardiologie, Hôpital Pitié-Salpétrière, Assistance Publique Hôpitaux de Paris, Université Pierre et Marie Curie Paris, France
IHU, Institute of Cardiometabolism And Nutrition, Hôpital Pitié-Salpétrière Paris, France
Background (1)The long-term risk of very late thrombosis after PCI does not decrease over time
Nearly half of the recurrent MACE after PCI for ACS are associated with non-culprit lesions at the time of PCI
Wenaweser P et al. JACC 2008;52 Stone G et al. N Engl J Med 2011;364
Background (2)DAPT trial: showed a reduction in rates of MACCE and stent thrombosis but an increase in bleeding
Mauri L et al. N Engl J Med 2014;371:2155
Hypothesis
• On a background of aspirin, continuing clopidogrel for up to 48 months would be superior to stopping clopidogrel at 12 months following drug-eluting stent (DES) implantation in reducing net adverse clinical events (composite of death, MI, stroke or major ISTH bleeding)– Randomized, multicentre, open-label study conducted in 58 sites
in France (January 2009–January 2013)– Funded by the French Ministry of Health. Additional unrestricted
research grants from Fédération Française de Cardiologie, Cordis, Boston, Medtronic, Terumo and Biotronik
Helft G et al, Trials 2013;14:56
Inclusion criteria• Patients with stable
CAD or ACS• With ≥1 lesion with a
significant stenosis in an artery ≥2.25 mm
• Implanted with ≥1 DES of any type
Exclusion criteria• DES implantation in an
unprotected left main coronary artery
• Requirement for oral anticoagulation
• Malignancies or other coexisting conditions associated with a life expectancy of <2 years
Patient selection
DES insertion
12 ± 3 monthsASPIRIN + CLOPIDOGREL
Randomization of patients free of MACCE or bleed
Follow-up (every 6 months between 12 and 48 months)
ASPIRIN + CLOPIDOGRELASPIRIN + CLOPIDOGREL
ASPIRIN ALONEASPIRIN ALONE
End of the study
0 12 months 48 months
Study design
Methods
• Primary endpoint– Net adverse clinical events: composite of all-cause
death, non-fatal MI, stroke, or major bleeding (ISTH classification)
• Secondary endpoints– Individual components of the primary outcome – Stent thrombosis (defined according to the Academic
Research Consortium [ARC])– Repeat revascularization of the treated vessel – Bleeding (ISTH, GUSTO, TIMI, BARC classifications)
Superiority trial: – 983 patients per arm – 80% power, alpha type-I error of 5%– Significant reduction in the primary composite
outcome at 3 years post-randomization from 7% with aspirin alone to 4% with extended DAPT
Owing to lack of resources and slower enrolment than anticipated, the executive committee and sponsor recommended termination of follow-up at the end of September 2014
Statistical analysis
Patient flow chart (CONSORT)
EXTENDED DAPT GROUPn=695
ASPIRIN GROUPn=690
P value
Age (years), mean (SD) 64.1 (10.8) 64.2 (11.5) 0.88
Women 18.3% 20.7% 0.23
Diabetes mellitus 30.6% 32.2% 0.54
Hypertension 57% 60.4% 0.19
Current/recent smoker 61.2% 57.8% 0.21
Previous PCI 25.9% 27.0% 0.66
Previous MI 17.1% 17.7% 0.78
Previous CABG 5.3% 5.1% 0.83
Stroke or TIA 4.2% 3.6% 0.60
Peripheral artery disease
4.9% 6.5% 0.19
Patient baseline characteristics
EXTENDED DAPT GROUP n=695 ASPIRIN GROUP n=690 P value
Indication for PCI
STEMI 10.7% 11.9% 0.47
Non-STEMI 14.2% 17.0% 0.39
Unstable angina 9.5% 9.1% 0.81
Stable angina 34.5% 30.0% 0.07
Silent ischaemia 19.9% 21.9% 0.35
Other 11.2% 10.1% 0.63
Type of DES
Sirolimus 19.9% 17.5% 0.17
Paclitaxel 15.2% 16.0% 0.65
Zotarolimus 8.3% 10.8% 0.05
Everolimus 50.2% 49.2% 0.66
Other 6.4% 6. 5% 0.93
Target vessel
Left main <1% >1% 0.69
LAD 58% 64% 0.007
LCX 33% 31% 0.59
RCA 41% 39% 0.58
Procedural characteristics
65.6%
34.4% 38.0%
62.0%
35.1% 33.5%
Treatment at randomization
R 0.75, 95% CI 0.50-1.28P=0.17
5.8%
7.5%
Primary outcome:Composite of death, MI, stroke, major bleed
Components of the primary endpoint
HR 0.65, CI 0.34-1.22 P=0.18
HR 0.69, CI 0.22-2.18 P=0.53
HR 0.67, CI 0.31-1.44 P=0.31
HR 0.98, CI 0.47-2.05 P=0.95
Death Stroke
MI Major bleed
4.2%
6.4%
HR 0.64, 95% CI 0.40-1.02P=0.06
Post-hoc analysis of ischaemic outcomes: death, stroke, or MI
Bleeding eventsExtended-DAPT
groupAspirin group Difference
Percentage points (95% CI)
P value
GUSTO moderate or severe
1.9% 1.7% 0.1 (-1.3 to 1.5) 0.85
Moderate 1.6% 1.2% 0.4 (-0.8 to 1.7) 0.49
Severe 0.4% 0.6% -0.2 (-0.9 to 0.6) 0.72
BARC type 2.6% 2.9% - 0.3 (-2.0 to 1.4) 0.72
2 0.7% 1.0% -0.3 (-1.3 to 0.7) 0.85
3 1.9% 2.0% -0.1 (-1.6 to 1.3) 0.83
5 0.1% 0 0.1 (-0.1 to 0.4) 1.00
TIMI major or minor 2.6% 2.9% -0.3 (-1.4 to 2.0) 0.72
Major 0.6% 0.6% 0.0 (-0.8 to 0.8) 1.00
Minor 2.2% 2.3% -0.1 (-1.7 to 1.4) 0.84
ISTH major 2.0% 2.0% 0.0 (-1.5 to 1.5) 0.98
ISTH moderate 0.9% 1.0% -0.1 (-1.1 to 0.9) 0.77
Meta-analysis of RCTs testing 12 months vs longer DAPT after DES:
Death, stroke, MI
Meta-analysis of RCTs testing 12 months vs longer DAPT after DES:
Death, stroke, MI
Study limitations
• Only powered to detect major differences in ischaemic and bleeding events
• Termination of the trial before enrolment and follow-up were completed reduced the trial power
• Open-label trial, although all clinical outcomes were adjudicated by an independent clinical event committee blinded to treatment assignment
Conclusions (1)
Extending DAPT duration for up to 48 months did not
achieve statistical superiority compared with stopping
clopidogrel at 12 months with regards to net adverse
clinical outcomes, in patients free of MACCE and
major bleed 12 months after stent implantation
Conclusions (2)
• Borderline but non-statistically significant
reduction in post-hoc analysis of ischaemic
outcomes with extended DAPT
• No apparent increase in bleeding and all-
cause mortality with extended DAPT
Main recruiting sitesCHU Pitié-Salpétrière, Paris, G Helft
CH Versailles, JL Georges
CHU Toulouse, D Carrié
Grenoble, Private office, X Dreyfus
CHU Angers, A Furber
CHU Montpellier, F Leclercq
CHU Rouen, H Eltchaninoff
Polyclinique de Bergerac, Falquier
CHU Lariboisière, Paris, P Henry
CH Le Raincy-Montfermeil, S Cattan
Clinique Turin, Paris, L Sebagh
CHU Tenon, Paris, PL Michel
CH Cherbourg, A Tuambilangana
CHU Nîmes, G Cayla
CHU Bordeaux, H Douard
CH Compiègne, A Luycx-Bore
Tarbes, Private office, N. LeyCH Bagnols sur Ceze, A. El Jabali CMC, Port Marly,, M. Brami CHU Kremlin Bicêtre,, A. Bouchachi, Villefranche de Rouergue, Private office, P.
BerangerCH Nanterre, F Digne Cherbourg, Private office, P. Pon-Bache
Gabrielsen CHU Nice, E Ferrari Creil, Private office, JPh Détienne CHU Caen, M HamonNantes, Private office, M. Benghanem Thionville, : P. Houplon CHU Bichat, Paris, G StegBiarritz, M. DucoudreSaint-Germain en Laye, Private office, M SanderAnd 27 other centres
• Steering Committee – G. Helft, P.G. Steg, J.Ph. Metzger, C. Le Feuvre, E. Vicaut
• Clinical Events Committee– L. Payot, O. Varenne, T. Petroni, O. Jobard, F. Laveau
• Data Monitoring Committee– C. Elie, N. Mansencal, E. Durand
• Study Staff– E. Berman , V. Raghavan, S. Djaileb
Trial organization